Skip to content

Study · Case report or series · n = 1 · 2024

7 results

Semaglutide as a potential therapeutic alternative for HNF1B-MODY: a case study.

Almutair A, Almulhem B

Frontiers in endocrinology8 Mar 2024Cited by 9 (Europe PMC)

PMID38524636 (opens in a new tab)PMCIDPMC10957750 (opens in a new tab)DOI10.3389/fendo.2024.1294264 (opens in a new tab)PepBankPUB-38524636
Download PDFPubMedAsk about this study
Jump to 7 results

Summary

Maturity-onset diabetes of the young (MODY) is a grouping of monogenic disorders. It is characterized by dominantly inherited, non-insulin-dependent diabetes. MODY is relatively rare, encompassing up to 3.5% in those diagnosed under 30 years of age. Specific types are most commonly treated with sulfonylurea, particularly those identified as HNF4A-MODY and HNF1A-MODY. HNF1B-MODY is another type that is most frequently managed with insulin therapy but lacks a defined precision treatment. We present an 18-year-old, non-obese female patient diagnosed with HNF1B-MODY. She displays complete gene deletion, a renal cyst, and hypomagnesemia. Her treatment plan includes both long- and short-acting insulin, though she frequently encountered hypoglycemia and hyperglycemia. Semaglutide, a GLP-1RA, was administered weekly over 4 months. The patient's glucose level was continuously tracked using Dexcom's Continuous Glucose Monitoring system. The data suggested a notable improvement in her condition: time-in-range (TIR) increased from 70% to 88%, with some days achieving 100%, and the frequency of hypoglycemic episodes, indicated by time-below-range values, fell from 5% to 1%. The time-above-range values also dropped from 25% to 10%, and her HbA1c levels declined from 7% to 5.6%. During the semaglutide therapy, we were able to discontinue her insulin treatment. Additionally, her body mass index (BMI) was reduced from 24.1 to 20.1 kg/m2. However, the semaglutide treatment was halted after 4 months due to side effects such as nausea, vomiting, and reduced appetite. Other contributing factors included exam stress and a COVID-19 infection, which forced a switch back to insulin. Her last recorded HbA1c level under exclusive insulin therapy rose to 7.1%, and her BMI increased to 24.9 kg/m2. In conclusion, semaglutide could potentially replace insulin to improve glucose variability, TIR, and HbA1c in patients with HNF1B-MODY. However, more extensive studies are required to confirm its long-term safety and efficacy.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

  1. 01HumanCase report or seriesEfficacy outcome

    In one patient with HNF1B-MODY, time-in-range rose from 70% to 88% during semaglutide treatment.

    In plain wordsIn one young woman with HNF1B-MODY, time in the target glucose range rose from 70% to 88% on semaglutide.

    Peptide
    Semaglutide
    Outcome
    IncreaseTime in range
    Study

    n = 1

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 4 monthsAs given in this study (human).

    Measurements

    Time in range before
    70%
    baseline
    Time in range after
    88%
    semaglutide

    Source sentences

    Summary
    The data suggested a notable improvement in her condition: time-in-range (TIR) increased from 70% to 88%
    2 context sentences
    Summary · context
    We present an 18-year-old, non-obese female patient diagnosed with HNF1B-MODY.
    Summary · context
    Semaglutide, a GLP-1RA, was administered weekly over 4 months.
  2. 02HumanCase report or seriesEfficacy outcome

    In one patient with HNF1B-MODY, time-below-range, a measure of hypoglycemic episodes, fell from 5% to 1% during semaglutide treatment.

    In plain wordsIn one young woman with HNF1B-MODY, time spent with low glucose fell from 5% to 1% on semaglutide.

    Peptide
    Semaglutide
    Outcome
    DecreaseTime below range
    Study

    n = 1

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 4 monthsAs given in this study (human).

    Measurements

    Time below range before
    5%
    baseline
    Time below range after
    1%
    semaglutide

    Source sentences

    Summary
    and the frequency of hypoglycemic episodes, indicated by time-below-range values, fell from 5% to 1%.
    2 context sentences
    Summary · context
    We present an 18-year-old, non-obese female patient diagnosed with HNF1B-MODY.
    Summary · context
    Semaglutide, a GLP-1RA, was administered weekly over 4 months.
  3. 03HumanCase report or seriesEfficacy outcome

    In one patient with HNF1B-MODY, time-above-range fell from 25% to 10% during semaglutide treatment.

    In plain wordsIn one young woman with HNF1B-MODY, time spent with high glucose fell from 25% to 10% on semaglutide.

    Peptide
    Semaglutide
    Outcome
    DecreaseTime above range
    Study

    n = 1

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 4 monthsAs given in this study (human).

    Measurements

    Time above range before
    25%
    baseline
    Time above range after
    10%
    semaglutide

    Source sentences

    Summary
    The time-above-range values also dropped from 25% to 10%
    2 context sentences
    Summary · context
    We present an 18-year-old, non-obese female patient diagnosed with HNF1B-MODY.
    Summary · context
    Semaglutide, a GLP-1RA, was administered weekly over 4 months.
  4. 04HumanCase report or seriesEfficacy outcome

    In one patient with HNF1B-MODY, HbA1c declined from 7% to 5.6% during semaglutide treatment.

    In plain wordsIn one young woman with HNF1B-MODY, HbA1c fell from 7% to 5.6% on semaglutide.

    Peptide
    Semaglutide
    Outcome
    DecreaseHbA1c change
    Study

    n = 1

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 4 monthsAs given in this study (human).

    Measurements

    HbA1c before
    7%
    baseline
    HbA1c after
    5.6%
    semaglutide

    Source sentences

    Summary
    and her HbA1c levels declined from 7% to 5.6%.
    2 context sentences
    Summary · context
    We present an 18-year-old, non-obese female patient diagnosed with HNF1B-MODY.
    Summary · context
    Semaglutide, a GLP-1RA, was administered weekly over 4 months.
  5. 05HumanCase report or seriesEfficacy outcome

    In one patient with HNF1B-MODY, insulin treatment could be discontinued during semaglutide therapy.

    In plain wordsIn one young woman with HNF1B-MODY, insulin could be stopped while she took semaglutide.

    Peptide
    Semaglutide
    Outcome
    DecreaseInsulin discontinuation
    Study

    n = 1

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 4 monthsAs given in this study (human).

    Source sentences

    Summary
    During the semaglutide therapy, we were able to discontinue her insulin treatment.
    2 context sentences
    Summary · context
    We present an 18-year-old, non-obese female patient diagnosed with HNF1B-MODY.
    Summary · context
    Semaglutide, a GLP-1RA, was administered weekly over 4 months.
  6. 06HumanCase report or seriesEfficacy outcome

    In one patient with HNF1B-MODY, BMI fell from 24.1 to 20.1 kg/m2 during semaglutide treatment.

    In plain wordsIn one young woman with HNF1B-MODY, BMI fell from 24.1 to 20.1 on semaglutide.

    Peptide
    Semaglutide
    Outcome
    DecreaseBMI change
    Study

    n = 1

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · 4 monthsAs given in this study (human).

    Measurements

    BMI before
    24.1 kg/m2
    baseline
    BMI after
    20.1 kg/m2
    semaglutide

    Source sentences

    Summary
    Additionally, her body mass index (BMI) was reduced from 24.1 to 20.1 kg/m2.
    2 context sentences
    Summary · context
    We present an 18-year-old, non-obese female patient diagnosed with HNF1B-MODY.
    Summary · context
    Semaglutide, a GLP-1RA, was administered weekly over 4 months.
  7. 07HumanCase report or seriesSafety outcome

    In one patient with HNF1B-MODY, semaglutide was halted after 4 months because of nausea, vomiting and reduced appetite.

    In plain wordsIn one young woman with HNF1B-MODY, semaglutide was stopped after 4 months because of nausea, vomiting and low appetite.

    Peptide
    Semaglutide
    Outcome
    IncreaseTreatment halted for nausea, vomiting and reduced appetite
    Study

    n = 1

    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    Dose not stated · 4 monthsAs given in this study (human).

    Source sentences

    Summary
    However, the semaglutide treatment was halted after 4 months due to side effects such as nausea, vomiting, and reduced appetite.
    2 context sentences
    Summary · context
    We present an 18-year-old, non-obese female patient diagnosed with HNF1B-MODY.
    Summary · context
    Semaglutide, a GLP-1RA, was administered weekly over 4 months.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.